Status:

Red

Decision Date:

March 2021

Comments

RED: 

• NICE TA677- Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma.  (NHSE commissioned).  (Decision date - March 2021). 

Red Drug Classifications

• 4: Specifically designated as “hospital only” by product licence or by DH/NICE
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again